MoonLake Immunotherapeutics (MLTX) Long-Term Investments (2020 - 2022)

MoonLake Immunotherapeutics' Long-Term Investments history runs 3 years deep, the most recent figure standing at $115.1 million for Q1 2022.

• On a quarterly basis, Long-Term Investments rose 12712721.99% year-over-year to $115.1 million in Q1 2022; TTM through Mar 2022 was $115.1 million, a 12712721.99% increase from a year earlier, with the FY2021 full-year figure at $115.0 million, up 25173337.2% from the prior year.
• Long-Term Investments steadied at $115.1 million in Q1 2022 per MLTX's latest filing, from $115.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $115.1 million in Q1 2022 and bottomed at $457.0 in Q4 2020.
• The 3-year median for Long-Term Investments is $115.0 million (2021), against an average of $76.7 million.
• Across the five-year window, Long-Term Investments soared 25173337.2% in 2021 and surged 12712721.99% in 2022, its largest moves.
• Year by year, Long-Term Investments stood at $457.0 in 2020, then surged by 25173337.2% to $115.0 million in 2021, then rose by 0.01% to $115.1 million in 2022.
• Per Business Quant, the three latest MLTX Long-Term Investments figures stand at $115.1 million (Q1 2022), $115.0 million (Q4 2021), and $115.0 million (Q3 2021).